Silk Road Medical, a leading minimally invasive medical device company focused on reducing the risk and impact of stroke, has announced the milestone that more than 100,000 TCAR procedures have been performed to date.
Since its inception, Silk Road has worked diligently to reduce the risk of stroke during treatment of carotid artery disease through innovative technology and minimally invasive techniques. Silk Road is credited with pioneering the TCAR procedure and building the ENROUTE Transcarotid Neuroprotection System (ENROUTE NPS) that supports the procedure with its patented flow reversal technology.
Compared to traditional open surgery (carotid endarterectomy or “CEA”), TCAR has demonstrated a lower risk of acute heart attack, less occurrences of nerve injury, shorter time required to perform the procedure, and a reduced length of stay at the hospital for patients according to Silk Road.
“A growing number of patients come to us looking for a solution that is minimally invasive and requires less downtime so they can get back to their daily lives,” said Dr. Gregg Landis, System Chief of Vascular Surgery at Northwell Health. “It’s incredible that Silk Road was able to not only address that need by creating the TCAR procedure, but also achieve such widespread adoption in a short period of time. TCAR has transformed the way we approach treating carotid artery disease while consistently delivering positive patient outcomes.”
The company says that every year, 15 million people worldwide suffer a stroke and carotid artery disease is attributed to more than 800,000 strokes in U.S. patients each year. The growing prevalence of carotid artery disease further reinforces the need for a more efficient, effective and scalable approach to stroke prevention.
“Completing the 100,000th TCAR procedure is the culmination of more than 15 years’ worth of work by members of the Silk Road Medical team and the healthcare providers we work with,” said Chas McKhann, CEO of Silk Road. “As we celebrate this important milestone, we remain excited and motivated to establish TCAR as the standard of care for addressing carotid artery disease.”